Erin Finot, Vice President of Immuno-Oncology & CAGT, IQVIA Biotech and IQVIA's Diego Correa, Vice President & Global Head, Cell & Gene Therapy Center of Excellence co-authored the article, Early Choices, Lasting Impact in Cell and Gene Therapy featured on Contract Pharma.

Click the button below to read how early decisions in manufacturing, regulatory strategy and clinical design shape long-term success in cell and gene therapy.

• Erin Finot, MS, MBA – Vice President, Immuno-Oncology & CAGT, IQVIA Biotech
• Diego Correa, MD, PhD, MSc – Vice President and Global Head, CAGT Center of Excellence, IQVIA